Clover Health Investments (CLOV) EBITDA (2019 - 2026)

Clover Health Investments has reported EBITDA for 8 years, with the latest figure at $26.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 10973.73% year-over-year to $26.1 million; the trailing twelve-month figure through Mar 2026 stood at -$57.5 million (down 154.29% YoY), and the FY2025 full-year result was -$83.4 million, down 97.61% from the prior year.
• EBITDA for Q1 2026 stood at $26.1 million, up from -$49.3 million in the prior quarter.
• The five-year high for EBITDA was $26.1 million in Q1 2026, with the low at -$105.5 million in Q2 2022.
• Historically, EBITDA has averaged -$38.4 million across 5 years, with a median of -$28.5 million in 2023.
• Annual changes were most pronounced in 2025 — EBITDA sank 298.46% — and 2026, when it soared 10973.73%.
• Clover Health Investments' EBITDA stood at -$82.8 million in 2022, then advanced by 18.19% to -$67.8 million in 2023, then surged by 63.81% to -$24.5 million in 2024, then plunged by 100.84% to -$49.3 million in 2025, then jumped by 153.05% to $26.1 million in 2026.
• The last three EBITDA figures came in at $26.1 million (Q1 2026), -$49.3 million (Q4 2025), and -$24.1 million (Q3 2025), per Business Quant data.